Rheumatoid arthritis medical therapy

Revision as of 13:38, 23 August 2012 by Aarti Narayan (talk | contribs) (Created page with "{{Rheumatoid arthritis}} {{CMG}}; {{AE}} {{AN}} ==Overview== There is no known cure for rheumatoid arthritis. However, many different types of treatment can be used to allevi...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Rheumatoid arthritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rheumatoid arthritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Primary prevention

Secondary prevention

Future or Investigational Therapies

Case Studies

Case #1

Rheumatoid arthritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rheumatoid arthritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Rheumatoid arthritis medical therapy

CDC on Rheumatoid arthritis medical therapy

Rheumatoid arthritis medical therapy in the news

Blogs onRheumatoid arthritis medical therapy

Directions to Hospitals Treating Rheumatoid arthritis

Risk calculators and risk factors for Rheumatoid arthritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Overview

There is no known cure for rheumatoid arthritis. However, many different types of treatment can be used to alleviate symptoms and/or to modify the disease process.

Medical Therapy

  • The goal of treatment in this chronic disease must be two-fold:
    • To alleviate the suffering of the patient here and now, and
    • To prevent the future destruction of the joints and resulting handicap if the disease is left unchecked.
  • These two goals may not always coincide: while pain relievers may achieve the first goal, they do not have any impact on the long-term consequences. For these reasons, most authorities believe that RA should be treated, in the vast majority of patients, by at least one specific anti-rheumatic medication, also named DMARD (see below), to which other medications and non-medical interventions can be added as needed.
  • Cortisone therapy has offered relief to many patients in the past, but its long-term effects have been deemed undesirable.[1]. However, cortisone injections can be valuable adjuncts to a long-term treatment plan, and using low dosages of daily cortisone (e.g., prednisone or prednisolone, 5-7.5 mg daily) can also have an important benefit if added to a proper specific anti-rheumatic treatment.
  • Pharmacological treatment of RA can be divided into disease-modifying antirheumatic drugs (DMARDs), anti-inflammatory agents and analgesics.[2][3]
  • DMARDs have been found to produce durable remissions and delay or halt disease progression.
  • In particular they prevent bone and joint damage from occurring secondary to the uncontrolled inflammation. This is important as such damage is usually irreversible.
  • Anti-inflammatory drugs and analgesics improve pain and joint stiffness but do not prevent joint damage or slow the disease progression. There is an increasing recognition amongst rheumatologists that permanent damage to the joints occurs at a very early stage in the disease.
  • In the past the strategy used was to start with just an anti-inflammatory drug, and assess progression clinically and using X-rays. If there was evidence that joint damage was starting to occur then a more potent DMARD would be prescribed.
  • Tools such as ultrasound and MRI are more sensitive methods of imaging the joints and have demonstrated that joint damage occurs much earlier and in more patients than was previously thought. Patients with normal X-rays will often have erosions detectable by ultrasound that X ray could not demonstrate.
  • There may be other reasons why starting DMARDs early is beneficial as well as prevention of structural joint damage. In the early stage of the disease, the joints are increasingly infiltrated by cells of the immune system that signal to one another and are thought to set up self-perpetuating chronic inflammation.
  • Interrupting this process as early as possible with an effective DMARD (such as methotrexate) appears to improve the outcome from the RA for years afterwards. Delaying therapy for as little as a few months after the onset of symptoms can result in worse outcomes in the long term. *There is therefore considerable interest in establishing the most effective therapy in patients with early arthritis, when they are most responsive to therapy and have the most to gain.[4]
  • Treatment also includes rest and physical activity. Regular exercise is important for maintaining joint mobility and making the joint muscles stronger. Swimming is especially good, as it allows for exercise with a minimum of stress on the joints.
  • Heat and cold applications are modalities that can ease symptoms before and after exercise. Pain in the joints is sometimes alleviated by oral acetaminophen (paracetamol). Other areas of the body, such as the eyes and lining of the heart, are treated individually. However, there is no diet that has been shown to alleviate rheumatoid arthritis, although fish oil may have anti-inflammatory effects.

Disease modifying anti-rheumatic drugs (DMARDs)

  • The term Disease Modifying Anti-Rheumatic Agent was originally introduced to indicate a drug that reduced evidence of processes thought to underly the disease, such as a raised erythrocyte sedimentation rate, reduced hemoglobin level, raised rheumatoid factor level and more recently, raised C-reactive protein level.
  • More recently, the term has been used to indicate a drug that reduces the rate of damage to bone and cartilage.
  • DMARDs can be further subdivided into traditional small molecular mass drugs synthesized chemically and newer 'biological' agents produced through genetic engineering.

Traditional small molecular mass drugs:

Biological agents

Biological agents (biologics include:

Anti-inflammatory agents and analgesics

Anti-inflammatory agents include:

Analgesics include:

The Prosorba column blood filtering device was approved by the FDA for treatment of RA in 1999 [6] However, in most patients the results have been very modest.

Historic treatments for RA have also included: RICE, acupuncture, apple diet, nutmeg, some light exercise every now and then, nettles, bee venom, copper bracelets, rhubarb diet, rest, extractions of teeth, fasting, honey, vitamins, insulin, magnets, and electroconvulsive therapy (ECT).[7]. Most of these have either had no effect at all, or their effects have been modest and transient in some individual patients, while not being generalizable.

References

  1. NIH: Results of Long-Continued Cortisone Administration in Rheumatoid Arthritis
  2. O'Dell J (2004). "Therapeutic strategies for rheumatoid arthritis". N Engl J Med. 350 (25): 2591–602. PMID 15201416.
  3. Hasler P (2006). "Biological therapies directed against cells in autoimmune disease". Springer Semin Immunopathol. 27 (4): 443–56. PMID 16738955. Unknown parameter |month= ignored (help)
  4. Vital E, Emery P (2005). "Advances in the treatment of early rheumatoid arthritis". Am Fam Physician. 72 (6): 1002, 1004. PMID 16190499. Unknown parameter |month= ignored (help)
  5. Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, Stevens R, Shaw T (2004). "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis". N Engl J Med. 350 (25): 2572–81. PMID 15201414.
  6. Fresenius HemoCare, Inc., "New Hope for Rheumatoid Arthritis Patients," press release, September 17, 1999.
  7. NIH: History of the treatment of rheumatoid arthritis

Template:WH Template:WS